JAK1 - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	JAK2	Janus kinase 2	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Polycythemia vera
Novel	JAK3	Janus kinase 3	Interleukin-7 signaling Interleukin-7 signaling Signaling by ALK RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-9 signaling Interleukin-2 signaling Interleukin-21 signaling Interleukin receptor SHC signaling Potential therapeutics for SARS	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one R-348 Ruxolitinib Tofacitinib Baricitinib Fostamatinib Abrocitinib Zanubrutinib	T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	JAKMIP1	janus kinase and microtubule interacting protein 1
Novel	MDK	midkine	Signaling by ALK Signaling by ALK NOTCH2 Activation and Transmission of Signal to the Nucleus MDK and PTN in ALK signaling MDK and PTN in ALK signaling
Novel	NFYC	nuclear transcription factor Y subunit gamma	PPARA activates gene expression Activation of gene expression by SREBF (SREBP) Activation of gene expression by SREBF (SREBP) ATF4 activates genes in response to endoplasmic reticulum stress ATF6 (ATF6-alpha) activates chaperone genes ATF6 (ATF6-alpha) activates chaperone genes FOXO-mediated transcription of cell death genes
Novel	OSMR	oncostatin M receptor	IL-6-type cytokine receptor ligand interactions
Novel	P2RY1	purinergic receptor P2Y1	G alpha (q) signalling events P2Y receptors ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1	Promethazine
Novel	P3H1	prolyl 3-hydroxylase 1	Collagen biosynthesis and modifying enzymes	Ascorbic acid Proline	Osteogenesis imperfecta
Novel	PDGFRA	platelet derived growth factor receptor alpha	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Tivozanib Fostamatinib Erdafitinib Amuvatinib Ripretinib	Glioma
Novel	PDGFRB	platelet derived growth factor receptor beta	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Glioma
Novel	PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K RHOF GTPase cycle Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by CSF1 (M-CSF) in myeloid cells RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK in cancer Signaling by LTK Co-stimulation by ICOS	SF1126 Enzastaurin Wortmannin
Novel	PLA2G4A	phospholipase A2 group IVA	phospho-PLA2 pathway Acyl chain remodelling of PC Acyl chain remodeling of CL Acyl chain remodelling of PS Acyl chain remodelling of PE Acyl chain remodelling of PI Acyl chain remodelling of PG Hydrolysis of LPC Synthesis of PA Arachidonate metabolism ADP signalling through P2Y purinoceptor 1 Platelet sensitization by LDL COPI-independent Golgi-to-ER retrograde traffic	Fluticasone propionate Procaine Quinacrine Niflumic acid Darapladib Fluticasone
Novel	PLAUR	plasminogen activator, urokinase receptor	Attachment of GPI anchor to uPAR Neutrophil degranulation Dissolution of Fibrin Clot	Urokinase Tenecteplase WX-UK1 Lanoteplase
Novel	PLCG2	phospholipase C gamma 2	GPVI-mediated activation cascade Toll Like Receptor 4 (TLR4) Cascade Synthesis of IP3 and IP4 in the cytosol Generation of second messenger molecules Role of phospholipids in phagocytosis DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization CLEC7A (Dectin-1) signaling CLEC7A (Dectin-1) signaling Dectin-2 family Dectin-2 family Erythropoietin activates Phospholipase C gamma (PLCG) FCGR3A-mediated IL10 synthesis Potential therapeutics for SARS Signaling by CSF1 (M-CSF) in myeloid cells Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Novel	PRKCZ	protein kinase C zeta	GPVI-mediated activation cascade TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) VEGFR2 mediated cell proliferation RHO GTPases Activate NADPH Oxidases Estrogen-stimulated signaling through PRKCZ Estrogen-stimulated signaling through PRKCZ	Tamoxifen Staurosporine Dequalinium Benzoyl peroxide
Novel	PRMT5	protein arginine methyltransferase 5	snRNP Assembly RMTs methylate histone arginines Regulation of TP53 Activity through Methylation
Novel	PTK2B	protein tyrosine kinase 2 beta	Signal regulatory protein family interactions VEGFA-VEGFR2 Pathway RHOU GTPase cycle Interleukin-2 signaling	Leflunomide Genistein 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide Fostamatinib
Novel	PTPN11	protein tyrosine phosphatase non-receptor type 11	Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Co-inhibition by CTLA4 Co-inhibition by PD-1 Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants SARS-CoV-2 activates/modulates innate and adaptive immune responses Co-inhibition by BTLA	Dodecyltrimethylammonium	Metachondromatosis Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	PTPN2	protein tyrosine phosphatase non-receptor type 2	Negative regulation of MET activity Interleukin-37 signaling PKR-mediated signaling		Type I diabetes mellitus
Novel	PTPN6	protein tyrosine phosphatase non-receptor type 6	GPVI-mediated activation cascade Regulation of KIT signaling Signaling by ALK PECAM1 interactions Co-inhibition by PD-1 Signal regulatory protein family interactions Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling CD22 mediated BCR regulation Neutrophil degranulation Interferon gamma signaling Regulation of IFNG signaling Interleukin-37 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Nuclear events stimulated by ALK signaling in cancer Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Co-inhibition by BTLA	Tiludronic acid

Search Results for: JAK1